Table 1 Demographical and clinical characteristics of endometriosis patients and controls
Endometriosis patients (n = 50) | Controls (n = 23) | |
|---|---|---|
Age in years, mean ± SD | 29.7 ± 6.2 | 30.9 ± 5.1 |
Parity, n (%) | ||
P0 | 38 (76%) | 15 (65.2%) |
P1 | 6 (12%) | 5 (21.7%) |
P2 | 6 (12%) | 3 (13.1%) |
rAFS score for endometriosis, median (IQR) | 14 (10–26) | NA |
rAFS stage for endometriosis, n (%) | ||
Stage I | 7 (14%) | NA |
Stage II | 19 (38%) | |
Stage III | 19 (38%) | |
Stage IV | 5 (10%) | |
Serum IL-37 (pg/mL), median (IQR) | 128.1 (93.9–198.7) | 64.6 (52.7–94.3) |
Peritoneal fluid IL-37 (pg/mL), median (IQR) | 146.2 (106.1–194.4) | 75.5 (61.8–108.2) |
IL-37 mRNA expression, (2−ΔCT) | 0.0239 (0.01393–0.03218) | 0.0029 (0.0017–0.0052) |
Peritoneal fluid TNF-α (pg/mL), median (IQR) | 55.55 (39.7–63.5) | 15.6 (12.8–19.3) |